Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics (NASDAQ: IOVA) granted inducement stock options on June 18, 2026 to twenty-seven new non-executive employees.

Rhea-AI Summary

Iovance Biotherapeutics (NASDAQ: IOVA) granted inducement stock options on June 18, 2026 to twenty-seven new non-executive employees. The options cover an aggregate 140,860 shares of common stock under the 2021 Inducement Plan, have a $3.91 exercise price, and vest over three years.

Positive

• Inducement options covering 140,860 shares help attract and retain 27 new employees
• Exercise price set at $3.91, aligned with market closing price on grant date
• Three-year vesting with quarterly installments supports long-term employee alignment

Negative

• Inducement stock options introduce potential dilution from up to 140,860 additional shares

Argus Jun 22 session

+3.84% close to close Open Argus

Details

News Market Reaction – IOVA

On Jun 22, the first trading day after this news, IOVA closed 3.84% above the previous close.

Data tracked by StockTitan Argus for the Jun 22 session.

Key Figures

Inducement option shares: 140,860 shares New employees: 27 employees Exercise price: $3.91 per share +5 more

Inducement option shares

140,860 shares

Aggregate options granted to new non-executive employees

New employees

27 employees

Recipients of inducement stock options

Exercise price

$3.91 per share

Option exercise price equal to June 18, 2026 close

Vesting period

3 years

Time-based vesting schedule for inducement options

Initial cliff vesting

1/3 of shares

Vest on first anniversary of employee start date

Subsequent installments

8 quarterly installments

Remaining options vest over following two years

Plan year

2021

Amended and Restated 2021 Inducement Plan

Listing rule

Nasdaq Rule 5635(c)(4)

Inducement award exemption for new employees

Historical Context

5 past events · Latest: Jun 03

5 events

1. Jun 03

   Regulatory approval

   24h Move

   +15.6%

   Australia granted conditional approval for Amtagvi in advanced melanoma patients.

2. Jun 01

   IND clearance

   24h Move

   -3.4%

   FDA cleared IND for IL-12 tethered TIL therapy IOV-5001 Phase 1/2 trial.

3. May 22

   Inducement grants

   24h Move

   -0.2%

   Inducement stock options for new employees under 2021 Inducement Plan granted.

4. May 21

   Conference appearance

   24h Move

   +4.5%

   Management scheduled to speak at the 2026 Jefferies Global Healthcare Conference.

5. May 07

   Earnings update

   24h Move

   -13.2%

   Strong Q1 revenue growth, guidance, and clinical updates highlighted by management.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

tumor infiltrating lymphocyte, nasdaq listing rule 5635(c)(4), exercise price

3 terms

tumor infiltrating lymphocyte medical

"delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients"

Tumor-infiltrating lymphocyte (TIL) is an immune cell found inside a tumor that can recognize and attack cancer cells; researchers can extract and multiply these patient-derived cells to use as a personalized therapy. Investors watch TILs because therapies built from them offer a targeted, individualized approach—like retraining a patient’s own soldiers to fight a specific enemy—which can influence clinical trial outcomes, regulatory decisions, and the commercial value of biotech companies.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"Each of the stock options granted as referenced in this press release has an exercise price of $3.91"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 18, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 140,860 shares of Iovance’s common stock to twenty-seven new, non-executive employees.

The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of $3.91, the closing price of Iovance’s common stock on the Date of Grant. Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee’s start date (the “First Vesting Date”) and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi^® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.

Amtagvi^® and its accompanying design marks, Proleukin^®, Iovance^®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

CONTACTS

Investors
IR@iovance.com
650-260-7120 ext. 150

Media
PR@iovance.com
650-260-7120 ext. 150

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement stock options did Iovance (NASDAQ: IOVA) grant on June 18, 2026?

Iovance granted inducement stock options covering 140,860 shares of common stock to twenty-seven new non-executive employees. According to Iovance, these options were approved on June 18, 2026 and issued under the Amended and Restated 2021 Inducement Plan for new hires.

How many IOVA shares are covered by the June 2026 inducement grants and at what exercise price?

The June 2026 inducement grants cover 140,860 Iovance common shares at an exercise price of $3.91 per share. According to Iovance, the exercise price equals the closing price of Iovance common stock on the June 18, 2026 grant date.

How do the June 2026 Iovance (IOVA) inducement stock options vest for employees?

The inducement stock options vest over three years, combining annual and quarterly schedules for employees. According to Iovance, one-third vests on the first anniversary of each employee’s start date, with the remaining shares vesting in eight quarterly installments over the next two years.

Under which plan and Nasdaq rule were the June 2026 Iovance inducement options granted?

The June 2026 inducement options were granted under Iovance’s Amended and Restated 2021 Inducement Plan. According to Iovance, this plan allows the compensation committee to grant equity awards to new employees in accordance with Nasdaq Listing Rule 5635(c)(4).

What could the June 18, 2026 Iovance (IOVA) inducement grants mean for existing shareholders?

The inducement grants could modestly dilute existing shareholders if all 140,860 options are exercised. According to Iovance, these options are part of a plan to grant equity awards to new employees, aligning their interests with shareholders over a three-year vesting period.